Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2026-02-02

Clinical Trial Update: Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy [Phase 3]

View source ↗

Summary

Open-label extension Phase 3 trial evaluating metreleptin in patients with familial partial lipodystrophy, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Metreleptin (metreleptin)

Snippet

Sponsor: Amryt Pharma | Conditions: Familial Partial Lipodystrophy | Phase 3 | Status: RECRUITING